Shionogi acquires global rights to QuatRx's lead programme
This article was originally published in Scrip
Executive Summary
Shionogi has locked up global rights to QuatRx Pharmaceuticals' lead development project in a deal which could eventually be worth more than $125 million to the private US firm.